Compare QUIK & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QUIK | ACOG |
|---|---|---|
| Founded | 1988 | 2000 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.3M | 115.5M |
| IPO Year | 1997 | N/A |
| Metric | QUIK | ACOG |
|---|---|---|
| Price | $7.43 | $6.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $11.00 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 121.0K | 85.2K |
| Earning Date | 02-24-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $16,178,999.00 | $7,427,199.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $73.16 | $132.35 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.26 | $3.75 |
| 52 Week High | $10.56 | $11.54 |
| Indicator | QUIK | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 68.32 | 59.27 |
| Support Level | $5.86 | $6.11 |
| Resistance Level | $6.63 | $6.91 |
| Average True Range (ATR) | 0.39 | 0.46 |
| MACD | 0.14 | 0.08 |
| Stochastic Oscillator | 97.83 | 85.16 |
QuickLogic Corp provides programmable silicon and software platforms to enable its customers to develop custom hardware products in a fast time-to-market and cost-effective way. QuickLogic is a fabless semiconductor company with a product range: embedded FPGA (eFPGA) intellectual property (IP), low power, multi-core semiconductor system-on-chips (SoCs), discrete FPGAs, and AI software. The full range of platforms, software tools, and eFPGA IP enables the practical and efficient adoption of AI, voice, and sensor processing across Aerospace, and Defense, Consumer/Industrial IoT, and Consumer Electronics markets.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.